About: Hematological findings and complications of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hematological findings and complications of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hematological findings and complications of COVID‐19
Creator	Dimopoulos, A Kastritis, Efstathios Ntanasis-Stathopoulos, Ioannis Psaltopoulou, Theodora Terpos, Evangelos Politou, Marianna Sergentanis, Theodoros Elalamy, \| Grigoris Gerotziafas, \| Meletios, \|
Source	Medline; PMC
abstract	COVID‐19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL‐6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID‐19 patients. Elevated D‐Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life‐threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1002/ajh.25829
bibo:pmid	32282949
has license	no-cc
sha1sum (hex)	b1212c0df1f8e55d19126c16a6a9ad9e61d97045
schema:url	https://doi.org/10.1002/ajh.25829
resource representing a document's title	Hematological findings and complications of COVID‐19
has PubMed Central identifier	PMC7262337
has PubMed identifier	32282949
schema:publication	Am J Hematol
resource representing a document's body	covid:b1212c0df1f8e55d19126c16a6a9ad9e61d97045#body_text
is schema:about of	named entity 'CONTINUOUS' named entity 'THROMBOCYTOPENIA' named entity 'HAVE' named entity 'HIGH RISK' named entity 'LEAD' named entity 'LDH' named entity 'RATIO' named entity 'CARDINAL' named entity 'D-DIMER LEVELS' named entity 'HEMATOPOIETIC SYSTEM' named entity 'IL-6' named entity 'ASSOCIATED WITH' named entity 'CASES' named entity 'FIBRIN DEGRADATION PRODUCTS' named entity 'NEUTROPHIL' named entity 'PROLONGED' named entity 'HIGH' named entity 'LONGITUDINAL EVALUATION' named entity 'POTENTIAL' named entity 'PLATELET' named entity 'PROGNOSTIC' named entity 'HEMOSTASIS' named entity 'INFECTED' named entity 'FERRITIN' named entity 'COVID' named entity 'multivariate analysis' named entity 'lymphocytes' named entity '85%' named entity 'COVID' named entity 'neutrophils' named entity 'antithrombin' named entity 'ARDS' named entity 'retrospective study' named entity 'MCP-1' named entity 'Coagulation disorders' named entity 'inflammatory mediators' named entity 'Mortality rates' named entity 'COVID' named entity 'viral transmission' named entity 'COVID-19' named entity 'CD8+ T-cells' named entity 'leukocyte' named entity 'lymphocyte' named entity 'thromboprophylaxis' named entity 'fibrin degradation products' named entity 'spleen' named entity 'venous thromboembolism' named entity 'CRP' named entity 'fibrin degradation products' named entity 'significant impact' named entity 'COVID-19' named entity 'Neutrophil' named entity 'prognosis' named entity 'thromboprophylaxis' named entity 'COVID-19' named entity 'Lymphopenia' named entity 'C-reactive protein' named entity 'Flow cytometry' named entity 'ICU' named entity 'myocarditis' named entity 'thrombomodulin' named entity 'meta-analysis' named entity 'platelet' named entity 'hematopoietic stem cell' named entity 'fulminant' named entity 'critically ill patients' named entity 'DIC' named entity 'myocardial injury' named entity 'lactic acid' named entity 'D-dimer' named entity 'ARDS' named entity 'critically ill patients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software